

Janet T. Mills
Governor

Sara Gagné-Holmes
Commissioner



Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463
TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

DUR COMMITTEE AGENDA

Date: Tuesday, September 8, 2026

Time: 5:30pm to 8:30pm

Location: **Virtual:**

To Dial in: 1-207-209-4724
Phone Conference ID: 543739755#
Teams link: [Join the meeting now](#)

In-Person:

109 Capitol Street
11 State House Station Rooms A and B
Augusta, Maine 04333

Closed Session – Board Members Only (5:30pm - 6:00pm) (separate invitation will be sent)

1) MaineCare Updates (Dan)

- HR1 Impact on MaineCare Member Coverage

Open Session (6:00pm - 8:30pm)

2) Public Comments (Mike welcomes reps to speak)

3) Old Business (Mike)

- Brinsupri revised criteria
- Imcivree revised criteria

4) Consent Agenda (Mike)

- Approve June 9, 2026, Meeting Minutes
- New Cancer Medications: General CA category/class criteria is published on the MaineCare PDL
 - Cavhanza (nilotinib)
 - Veppanu (vepdegestrant)
 - Yulithira (everolimus)
- Biosimilars
 - Filkri (filgrastim-laha); Granulocyte CSF
 - Neupogen (filgrastim)
 - Eylea (aflibercept ophthalmic); OP – Of Interest
 - Yesafili (aflibercept-jbvf)
 - Lucentis (ranibizumab injection); OP – Of Interest
 - Nufymco (ranibizumab-leyk)
 - Prolia (denosumab); Osteoporosis / Bone Agents
 - Osvyrti (denosumab-desu)
 - Xgeva (denosumab); Osteoporosis / Bone Agents
 - Jubereq (denosumab-desu)
- No Clinical Reviews Needed / No New Criteria
 - Atonyx (atomoxetine hydrochloride); Stimulant Like

5) Revised clinical criteria (Dr. Capp)

- None

6) New Business Retro DUR (Dr. Capp)

- Data Presentation: Biologic Utilization in Adults with Inflammatory Bowel Disease Biologic Treatment Patterns
- Introduction: Co-prescribing of medium-high dose pregabalin and gabapentin among those on opioid drugs

7) New Drug Review

- | | | |
|-----------|-------------|-----------|
| ○ Awiqli | ○ Baxfendy | ○ Bysanti |
| ○ Fesilty | ○ Hepcludex | ○ Idvynso |
| ○ Lynavoy | ○ Xocova | ○ Zolybus |

8) FDA Safety Alerts (FYI Only)

- None

9) Next Meeting: **Tuesday, November 3, 2026 | 1:00pm to 5:00pm | ANNUAL MEETING**

Tuesday, December 8, 2026 | 5:30pm to 8:30pm

Adjournment: 8:30pm